Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K E Kester

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 3, 2001
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge modelJ D Berman, R Nielsen, J D Chulay, et al.
The New England Journal of Medicine|January 9, 1997
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation GroupJ A Stoute, M Slaoui, D G Heppner, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Vaccine|October 16, 1999
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoidW A Keitel, K E Kester, R L Atmar, et al.
Vaccine|April 7, 2024
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adultsJ F Cummings, M E Polhemus, K E Kester, et al.
The Journal of Infectious Diseases|October 9, 1999
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccineA Lalvani, P Moris, G Voss, et al.
The American Journal of Tropical Medicine and Hygiene|January 14, 1999
Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19)A Gozalo, C Lucas, M Cachay, et al.
Lancet (London, England)|December 19, 2001
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trialK A Bojang, P J Milligan, M Pinder, et al.
The Journal of Infectious Diseases|November 7, 1998
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccineJ A Stoute, K E Kester, U Krzych, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 3, 2001
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge modelJ D Berman, R Nielsen, J D Chulay, et al.
The New England Journal of Medicine|January 9, 1997
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation GroupJ A Stoute, M Slaoui, D G Heppner, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Vaccine|October 16, 1999
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoidW A Keitel, K E Kester, R L Atmar, et al.
Vaccine|April 7, 2024
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adultsJ F Cummings, M E Polhemus, K E Kester, et al.
The Journal of Infectious Diseases|October 9, 1999
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccineA Lalvani, P Moris, G Voss, et al.
The American Journal of Tropical Medicine and Hygiene|January 14, 1999
Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19)A Gozalo, C Lucas, M Cachay, et al.
Lancet (London, England)|December 19, 2001
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trialK A Bojang, P J Milligan, M Pinder, et al.
The Journal of Infectious Diseases|November 7, 1998
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccineJ A Stoute, K E Kester, U Krzych, et al.
Pageof 3